logo-loader
RNS
viewSynairgen PLC

Synairgen plc - Holding(s) in Company

RNS Number : 3878U
Synairgen plc
17 January 2017
 

 

 

 

 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
ii

Synairgen plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

x

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

3. Full name of person(s) subject to the
notification obligation:
iii

Richard Griffiths and controlled undertakings

4. Full name of shareholder(s)
 (if different from 3.):iv

 

5. Date of the transaction and date on
which the threshold is crossed or
reached:
v

16 January 2017

6. Date on which issuer notified:

17 January 2017

7. Threshold(s) that is/are crossed or
reached:
vi, vii

 > 11%

           
 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary 1p

9,450,512

9,450,512

10,136,512

10,136,512

 

11.09%

 

GB00B0381Z20

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date
xiii

Exercise/
Conversion Period
xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period
xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

10,136,512

11.09%

                                 
 

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi

 

Blake Holdings Limited

        4,146,512

Seren Investment Management Limited

        5,345,000

Richard Griffiths direct holdings

           645,000

 

 

Total

      10,136,512

 

 

The above undertakings are all controlled by Richard Griffiths

 

 

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will cease
to hold:

 

12. Date on which proxy holder will cease to hold
voting rights:

 

 


13. Additional information:

 

14. Contact name:

James Sutcliffe

15. Contact telephone number:

+44 1534 719761

     

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFSSLEIDLID

Quick facts: Synairgen PLC

Price: 39.5

Market: AIM
Market Cap: £59.03 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18